Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Non Operating Income (2018 - 2023)

Addex Therapeutics' Non Operating Income history spans 5 years, with the latest figure at -$289730.1 for Q4 2023.

  • On a quarterly basis, Non Operating Income rose 1.72% to -$289730.1 in Q4 2023 year-over-year; TTM through Dec 2023 was -$1.4 million, a 4.99% decrease, with the full-year FY2025 number at -$18751.7, down 171.27% from a year prior.
  • Non Operating Income came in at -$289730.1 for Q4 2023, up from -$294798.2 in the prior quarter.
  • The five-year high for Non Operating Income was -$177827.5 in Q4 2019, with the low at -$681391.9 in Q4 2020.
  • Historically, Non Operating Income has averaged -$360936.9 across 4 years, with a median of -$292264.2 in 2022.
  • Biggest five-year swings in Non Operating Income: rose 19.56% in 2019 and later plummeted 283.18% in 2020.
  • Year by year, Non Operating Income stood at -$177827.5 in 2019, then plummeted by 283.18% to -$681391.9 in 2020, then skyrocketed by 56.74% to -$294798.2 in 2022, then rose by 1.72% to -$289730.1 in 2023.
  • Business Quant data shows Non Operating Income for ADXN at -$289730.1 in Q4 2023, -$294798.2 in Q4 2022, and -$681391.9 in Q4 2020.